Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Identifying safe long term investments is essential for risk-averse investors. Learn about reliable options to secure your financial future.
26,844 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
As mdxhealth (MDXH) 2025 earnings unfold, investors watch cash burn, pipeline progress, and strategic partnerships. T...
Diplomacy with Iran could spark big moves in oil this week. If talks gain momentum, prices could ease; if they stall,...
Investors are weighing two very different quantum paths. This guide compares D-Wave Quantum and IonQ, highlighting te...
A major shift in early trading set the tone for Accenture's latest results. This article explains why accenture stock...
As an investor, timing updates can boost or trim returns. This guide breaks down whether should taiwan semiconductor ...
Today’s surge surprised many investors as Paramount Skydance climbed sharply while broader markets slipped. This arti...
Avis Budget Group stock surged this week as travel demand picked up and airport bottlenecks nudged customers toward r...
A bold $1.5 billion investment signals Boston Scientific’s shift into transcatheter aortic valve replacement. Explore...
The Federal Reserve unveiled a sweeping policy overhaul under Chair Kevin Warsh, signaling a shift away from traditio...
SpaceX hovers around $135 ahead of a pivotal Starship test. This report weighs the case for spacex $135: should space...
A 200% jump in 2025 Russian airspace incursions into NATO territory marks a rapid escalation. Investors are reassessi...